12/1/2009

The FDA cleared Eli Lilly and Co. to market Cymbalta as a maintenance therapy for generalized anxiety disorder. Cymbalta, which was first approved in 2004 as an antidepressant, already has FDA approval to treat acute attacks of generalized anxiety disorder.

Related Summaries